Format

Send to

Choose Destination
Front Neurol. 2017 May 31;8:230. doi: 10.3389/fneur.2017.00230. eCollection 2017.

The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis.

Author information

1
Department of Neurology, The George Washington University, Washington, DC, United States.
2
Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
3
Department of Neurology, Qilu Hospital of Shandong University, Jinan, China.
4
The Key Laboratory of Geriatrics, Beijing Hospital, Beijing Institute of Geriatrics, Ministry of Health, Beijing, China.
5
Department of Pharmacology, The George Washington University, Washington, DC, United States.
6
Department of Physiology, The George Washington University, Washington, DC, United States.
7
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China.
8
Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.

Abstract

Biomarkers that assess treatment response for patients with the autoimmune disorder, myasthenia gravis (MG), have not been evaluated to a significant extent. We hypothesized the pro-inflammatory cytokine, osteopontin (OPN), may be associated with variability of response to glucocorticoids (GCs) in patients with MG. A cohort of 250 MG patients treated with standardized protocol of GCs was recruited, and plasma OPN and polymorphisms of its gene, secreted phosphoprotein 1 (SPP1), were evaluated. Mean OPN levels were higher in patients compared to healthy controls. Carriers of rs11728697*T allele (allele definition: one of two or more alternative forms of a gene) were more frequent in the poorly GC responsive group compared to the GC responsive group indicating an association of rs11728697*T allele with GC non-responsiveness. One risk haplotype (AGTACT) was identified associated with GC non-responsiveness compared with GC responsive MG group. Genetic variations of SPP1 were found associated with the response to GC among MG patients.

KEYWORDS:

glucocorticoid; myasthenia gravis; osteopontin; quantitative myasthenia gravis score; secreted phosphoprotein 1

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center